Ilumya Disease Interactions
There are 3 disease interactions with Ilumya (tildrakizumab).
Tildrakizumab (applies to Ilumya) tuberculosis
Major Potential Hazard, Moderate plausibility. Applicable conditions: Tuberculosis -- Active, Tuberculosis -- Latent, History - Tuberculosis
Do not administer tildrakizumab to patients with active TB infection. It is recommended to assess patients for tuberculosis (TB) infection before starting treatment with this agent. Consider anti-TB therapy prior to initiation of tildrakizumab in patients with latent TB, a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after treatment with tildrakizumab.
Tildrakizumab (applies to Ilumya) infections
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral
The use of tildrakizumab may increase the risk of infection. Treatment with tildrakizumab should not be started in patients with active infection until the infection resolves or is adequately treated. Consider the risks and benefits prior to using this agent in patients with chronic infection or a history of recurrent infection. It is recommended to monitor the patient closely and consider discontinuation of tildrakizumab if a patient develops a clinically important or serious infection or is not responding to standard therapy.
Tildrakizumab (applies to Ilumya) vaccination
Moderate Potential Hazard, Moderate plausibility.
It is recommended to avoid the use of live vaccines in patients treated with tildrakizumab. Before starting therapy with tildrakizumab, consider completion of all age appropriate immunizations according to current immunization guidelines. Care should be exercised as no data are available on the response to live or inactive vaccines.
Switch to professional interaction data
Ilumya drug interactions
There are 186 drug interactions with Ilumya (tildrakizumab).
More about Ilumya (tildrakizumab)
- Ilumya consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (8)
- Drug images
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- FDA approval history
- Drug class: interleukin inhibitors
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Humira
Humira is a tumor necrosis factor blocker that is used to treat many inflammatory conditions such ...
Cosentyx
Cosentyx (secukinumab) is used to treat plaque psoriasis, psoriatic arthritis, ankylosing ...
Otezla
Otezla (apremilast) is used to treat plaque psoriasis, psoriatic arthritis, and oral ulcers ...
Skyrizi
Skyrizi (risankizumab) is used to treat plaque psoriasis, psoriatic arthritis, ulcerative colitis ...
Stelara
Stelara (ustekinumab) is used to treat Crohn's disease, ulcerative colitis, plaque psoriasis, and ...
Taltz
Taltz (ixekizumab) is used to treat plaque psoriasis, psoriatic arthritis, and ankylosing ...
Vtama
Vtama (tapinarof) is a steroid-free, once-daily cream used to treat plaque psoriasis and atopic ...
Enbrel
Enbrel is used to treat rheumatoid arthritis, ankylosing spondylitis, and psoriasis. Learn about ...
Tremfya
Tremfya (guselkumab) injection is used to treat plaque psoriasis, psoriatic arthritis, ulcerative ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.